Back to dashboard
MedicaidCoverageMedium impact

Directing Acting Antiviral (DAA) Coverage Correction

Maryland Medicaid·MD · Gastroenterology, Infectious Disease, Internal Medicine +1 more·Provider Transmittal
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy corrects coverage for Direct Acting Antiviral (DAA) medications used to treat Hepatitis C. The transmittal clarifies billing procedures and coverage criteria for these specialized antiviral treatments.

Action Required

Action needed
Review the full policy document at https://health.maryland.gov/mmcp/provider/Documents/pt_31-17.pdf to understand specific DAA coverage corrections and update billing procedures accordingly. Verify current coverage criteria for Hepatitis C antiviral medications and ensure proper prior authorization processes are followed.

Related policy hubs